Lundbeck

A global biopharmaceutical company specialized in neuroscience

Unternehmenstyp

Großunternehmen


Branche

Medizin / Pharma / Gesundheit / Pflege


Standort

Ottiliavej 9, 2500 Copenhagen, Denmark

Lundbeck entdecken

Das Video abspielen
Vorschaubild des Videos

Lundbeck is a biopharmaceutical company focused exclusively on neuroscience. We discover, develop, and commercialize treatments that improve the lives of people affected by neurological and psychiatric diseases.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options.

We are 5,600 employees in more than 50 countries, and our products are available in more than 100 countries. We have research facilities in Denmark and the United States, and our production facilities are located in Denmark, France, and Italy. Whether we work in labs, at desks, or in the field, we work closely with patients, healthcare professionals, and the neuroscience community to uncover causes, find new treatments, and fight stigma and discrimination against people living with brain diseases.

We build on our Danish heritage and more than 70 years in neuroscience, fostering a culture of collaboration, responsibility, and respect.

For additional information, we encourage you to visit our corporate website www.lundbeck.com and connect with us via LinkedIn.

Wie ist es, hier zu arbeiten?

Das Wichtigste auf einen Blick

Das Video abspielen
Vorschaubild des Videos

Living with chronic migraine - Hero Campaign

Das Video abspielen
Vorschaubild des Videos

Lundbeck - World Mental Health Day 2021

  • Gründungsjahr

    1915

  • Geschlechterverteilung

    46%

    54%

  • Internationale Präsenz

    50 Länder

  • Unternehmenswerte

    Patient-driven • Courageous • Ambitious • Passionate

Ihre CSR Maßnahmen

Bereits 3 Maßnahmen umgesetzt 💚

  • Gender balance targets: min. 40% of underrepresented gender.

  • Reduction in scope 1 and 2 carbon emissions

  • Inclusive redesign of key people processes